New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The facility will accommodate over 1,500 employees
Subscribe To Our Newsletter & Stay Updated
